A ntibodies have had a transformative impact on science and medicine because of their exceptional specificity and biochemical versatility, enabling applications in almost every aspect of biomedical inquiry. Conventional antibodies are composed of two heavy chains and two light chains. Each of these components contributes to antigen-binding specificity through a variable domain, termed V H and V L for the variable domains of the heavy chain and light chain, respectively. A key exception to this general architecture is found in camelids (llamas, camels, alpacas, and their relatives), which possess a parallel antibody repertoire composed solely of heavy chains 1,2 . Such antibodies bind to their target antigens through a single variable domain, termed V HH , which contains the entire antigen-binding surface. Unlike the antigen-binding fragments (Fabs) of conventional antibodies, isolated V HH domains (also called nanobodies) can be readily expressed in bacteria as the product of a single gene, and in many cases, these fragments can even fold and retain antigen specificity in the reducing environment of the eukaryotic cytosol. Owing to their versatility, nanobodies have found applications in protein structural biology and cell biology and as potential diagnostic and therapeutic agents 2-6 . Nanobodies have been particularly critical tools in studies of GPCRs, in which conformationally selective nanobodies have been used extensively to stabilize these receptors in defined states for crystallographic studies that would otherwise be impossible 6 .
A ntibodies have had a transformative impact on science and medicine because of their exceptional specificity and biochemical versatility, enabling applications in almost every aspect of biomedical inquiry. Conventional antibodies are composed of two heavy chains and two light chains. Each of these components contributes to antigen-binding specificity through a variable domain, termed V H and V L for the variable domains of the heavy chain and light chain, respectively. A key exception to this general architecture is found in camelids (llamas, camels, alpacas, and their relatives), which possess a parallel antibody repertoire composed solely of heavy chains 1, 2 . Such antibodies bind to their target antigens through a single variable domain, termed V HH , which contains the entire antigen-binding surface. Unlike the antigen-binding fragments (Fabs) of conventional antibodies, isolated V HH domains (also called nanobodies) can be readily expressed in bacteria as the product of a single gene, and in many cases, these fragments can even fold and retain antigen specificity in the reducing environment of the eukaryotic cytosol. Owing to their versatility, nanobodies have found applications in protein structural biology and cell biology and as potential diagnostic and therapeutic agents [2] [3] [4] [5] [6] . Nanobodies have been particularly critical tools in studies of GPCRs, in which conformationally selective nanobodies have been used extensively to stabilize these receptors in defined states for crystallographic studies that would otherwise be impossible 6 .
Despite the growing importance of nanobodies throughout biomedical research, the current methods for creating these powerful tools remain slow, costly, and often unreliable. The majority of nanobodies described to date have been derived from the immunization of camelids, a lengthy and expensive process posing a significant barrier to entry for most laboratories. More importantly, animal-derived antibodies are frequently restricted from binding conserved epitopes because of the immunological tolerance of selfantigens. As conserved epitopes often drive key protein functions like protein-protein recognition and allosteric communication, a rapid method to identify nanobodies that target such sites would provide a robust means to interrogate protein function.
Previous efforts have sought to address challenges in nanobody identification by combining phage display with a synthetic library 7 . However, these libraries remain available only through contract work with an expensive commercial provider, thereby limiting their broad utilization. Moreover, with synthetic libraries, it remains particularly challenging to identify nanobodies that not only bind to their target, but also specifically recognize a defined conformation, which represents one of the most important applications of animal-derived nanobodies. Phage-display techniques enable isolation of high-affinity binders, but identification of functional clones (for example, conformationally selective nanobodies) remains challenging, despite select successes 8, 9 . Here, we address these challenges through the development and application of a fully synthetic yeast-display nanobody library, devised using an alignment of structurally characterized nanobodies from the Protein Data Bank (PDB). The use of a cell-based selection scheme enabled by fluorescence-activated cell sorting (FACS) allows straightforward and rapid identification of conformationally selective nanobodies for two human GPCRs. To enable broad utility of this new resource, we have made the library and all associated protocols available to the scientific community. from llama genes IGHV1S1-IGHV1S1S5. This constant framework was combined with designed variation of the complementarity-determining loops (CDRs) that comprise the highly variable antigen-binding interface of the V HH . Although there are many previously described strategies for introducing variation in antibody CDR loops 10 , we postulated that nanobodies of known structure in PDB represent an especially curated set of highly stable, biochemically well-behaved variants, as evidenced by their tractability in crystallographic studies. The entire set of unique nanobodies in PDB (93 sequences at the time of analysis) was analyzed for position-specific variation in the CDRs, and our design aimed to recapitulate this diversity. For the residues immediately adjacent to the CDRs, we introduced partial randomization, allowing only a few possible amino acids guided by the observed frequencies of nanobodies in the PDB. For the highly variable positions in each CDR, we introduced much more thorough randomization reflective of the high diversity at these positions. First, the frequency of each amino acid within CDR3 was determined for all nanobodies in the PDB. The resulting mixture of amino acids was modified to eliminate cysteine and methionine to avoid chemical reactivity and was introduced into various positions in each CDR in the synthetic library. On the basis of nanobody sequence analysis, we elected to introduce four such highly variable positions in CDR1 and one in CDR2. The longer CDR3 represents a critically important loop for antigen recognition, in which we introduced 7, 11, or 15 consecutive positions of high-diversity mixture to emulate CDR3 length variation seen in the natural repertoire ( Fig. 1a-c) . Primers encompassing the desired sequence diversity were synthesized, with high-diversity regions constructed using a mixed pool of trimer phosphoramidites to match target codon frequency 11, 12 . We then built a pooled DNA library encoding the full nanobody sequence by assembly PCR of these primers ( and after four rounds of selection (blue). The percentage of HSA-binding cells is indicated. The fraction of the total library composed by Nb.b201 was assessed by deep sequencing, showing progressive enrichment of this clone. b, Size-exclusion chromatography analysis confirmed the binding of purified recombinant Nb.b201 to HSA. c, Crystal structure of nanobody-HSA complex (PDB 5VNW), including close-up view of the CDR loops interacting with antigen. Hydrogen bonds are shown as dotted lines. d, Rotated view of the complex shown in c. e, Comparison of nanobody structures in the antigenbound (yellow) and antigen-free state (gray, PDB 5VNV), showing conformational change upon antigen binding. Changes are highlighted with arrows, and CDR loops are colored blue, green, and orange for CDR1, CDR2, and CDR3, respectively (more details in Table 1 and Supplementary Fig. 3 ). Methods). A pervasive but often unappreciated drawback of synthetic antibody fragments is poor biochemical behavior. Prior to generating a large yeast display library, we sought to assess whether our library design would reliably produce biochemically tractable clones suitable for structural and cell biological studies. A total of 11 nanobody sequences were chosen at random from the library DNA and tested for biochemical behavior by expression and purification from Escherichia coli. Of these clones, nine were well expressed ( > 20 mg/L), could be purified by routine procedures, and showed reasonably monodisperse size-exclusion profiles (Supplementary Fig. 1 and Supplementary Table 1 ).
Next, we sought to develop a straightforward way to tether nanobodies and other small proteins to the surface of Saccharomyces cerevisiae and other yeast species. A variety of methods for this purpose have been reported previously, with the most common approach being fusion of a protein of interest to Aga2p, a yeast cell wall protein 13 . Although this strategy has been widely used, including to select for nanobodies specific for agonist-bound muscarinic acetylcholine receptor 14 , it is limited by the requirement to use engineered yeast strains expressing galactose-inducible Aga1p, which tethers Aga2p to the yeast cell wall. Instead, we built a simplified system in which the protein of interest is directly connected to the cell wall through a single tether designed to replace the Aga2p-Aga1p linker protein.
A synthetic tether mimicking the low-complexity sequence of yeast cell wall proteins was designed and evaluated for its ability to anchor a test protein to the yeast cell wall (full sequence in Supplementary Note). Accessibility of this protein correlated strongly with the molecular weight of the staining reagent, suggesting steric occlusion by cell wall glycans. Consistent with this explanation, longer tethers alleviated this problem, and at linker lengths over 600 amino acids, the molecular weight dependence of staining levels was negligible ( Supplementary Fig. 2 ). For library creation, we chose to use a 649amino acid tether. In addition, we included an N-terminal engineered mating factor α preprotein that has been reported to enhance antibody expression in yeast 15 . On the C terminus, we included a glycosylphosphatidylinositol anchor sequence, which resulted in covalent tethering of the protein to the yeast cell wall 16 (Fig. 1d ). On the basis of these results, we linearized the engineered surface display plasmid (pYDS649), which was then transformed into the Saccharomyces cerevisiae protease-deficient strain BJ5465 together with the DNA library, which had been amplified to include flanking sequences homologous to pYDS649 for recombination. This resulted in a yield of 5 × 10 8 transformants. While this yield is modest in comparison to some libraries, we show that our approach yields comparable clones to those obtained by animal immunization, attesting to the value of our structure-based library design.
To characterize the resulting yeast surface displayed library, we isolated plasmid DNA from ~600,000 yeast cells and performed high-throughput sequencing. Analysis of 480,000 unique sequences confirmed that the library clones possessed the desired amino acid frequencies in the hypervariable portions of the CDR loops ( Fig. 1c ) and also that CDR-flanking-region diversity resembled target frequencies. Overall, 26% of library yeast showed high expression of nanobodies as measured by flow cytometry. Taken together, these data imply that the library contains at least 1 × 10 8 unique fulllength nanobody clones that are able to be expressed and displayed on the yeast surface.
Identification of nanobodies using magnetic cell sorting. We next sought to determine whether our approach could yield nanobody clones targeting diverse antigen classes, including both soluble and membrane proteins. As an initial test, we aimed to identify nanobodies targeting human serum albumin (HSA), the most abundant protein in human plasma. Binding of therapeutic proteins and small molecules to HSA is a key determinant of drug pharmacokinetics; nanobodies targeting HSA may therefore provide a modular tool for enhancing the half-life of biologics [17] [18] [19] . In this first test, we exclusively employed magnetic cell sorting (MACS), a low-cost cell separation method that can be performed in even the most basic laboratory environments without specialized equipment 20 .
To identify novel HSA-binding nanobodies, we first prepared fluorescently labeled HSA protein and then used this reagent to perform iterative staining and magnetic-bead-based enrichments. In brief, this approach entails incubation of the yeast library with fluorescent HSA antigen, washing off excess antigen, and further staining desired clones with anti-fluorophore magnetic microbeads. Labeled cells are then isolated by magnet-based separation and amplified in standard yeast culture medium ( Fig. 1e ). As with any library-based selection, it is of paramount importance to ensure that binders recognize the antigen itself, rather than the reagents or fluorescent tags used for separation. To achieve such specificity, yeast with reactivity to beads alone were depleted from the library before each selection step. To decrease the probability of enriching fluorophore binders, the fluorophore tag used was alternated between Alexa Fluor 647 and fluorescein isothiocyanate (FITC) for each consecutive round of magnetic selection. After four rounds of selection ( Fig. 2a ), single yeast colonies were isolated and stained with fluorescently labeled HSA for validation by analytical flow cytometry. For further study, we selected one clone with strong antigen binding (named Nb.b201) for in-depth characterization. As expected, Nb.b201 was expressed and purified from E. coli using standard methods, with a yield of 26 mg of purified protein per liter of culture. We assessed HSA binding in vitro by analytical size-exclusion chromatography ( Fig. 2b ) and more quantitatively by surface plasmon resonance (SPR, Supplementary Fig. 3 ). Both techniques confirmed specific binding of Nb.b201 to HSA. Although the binding affinity was modest at 430 nM, Nb.b201 was highly specific, demonstrating no binding to the closely related mouse serum albumin (MSA, Supplementary Fig. 3 ), and formed a stable complex with HSA, as assessed by size-exclusion chromatography (Fig. 2b) .
A major goal of our approach presented here was to facilitate structural biology efforts; thus, we assessed the structural basis * * * * * * * * * * * * * * * * * * * β 2 AR 1 mm
Fig. 3 | Structural and functional modulator nanobodies targeting a GPCR. a, β 2 AR interconverts between ensembles of inactive conformations (red)
and active conformations (green). The active state of the receptor can be stabilized by nanobodies (yellow) that bind to the intracellular face of the receptor. b, Results of selection summarized in flow cytometry plots. After FACS selection, a substantial fraction (23.6%) of clones show agonist-specific binding to the β 2 AR. c, Selection schematic for isolation of active-state stabilizing nanobodies. In MACS rounds (1, 2, and 5), depletion and enrichment steps were performed sequentially. In FACS rounds, two-color sorting was used to enrich agonist-specific clones and deplete antagonist-specific and nonselective clones simultaneously. Cz, carazolol (antagonist); BI, BI167107 (agonist Fig. 5 ). h, Nb.c200 immobilized by metal ion affinity chromatography pulled down purified β 2 AR before crystallographic trials. i, Nb.c200 enabled crystallization of the β 2 AR using the lipidic cubic phase method. j, cAMP signaling assay to measure β 2 AR signaling in the presence or absence of synthetic nanobodies. Data are shown as mean ± s.e.m. for transfections performed in triplicate ( Supplementary Fig. 4 ).
for Nb.b201 binding to HSA. Nb.b201 crystallized readily, both in isolation and in complex with HSA. X-ray data collection yielded datasets to a resolution of 1.4 Å and 2.6 Å for the free nanobody and HSA complex, respectively (Table 1) . These crystal structures revealed that Nb.b201 adopts the typical V-set immunoglobulin fold previously observed for animal-derived nanobodies ( Fig. 2c-e ). Comparison of the two structures provides an opportunity to compare bound and free states of the same antibody fragment. Remarkably, Nb.b201 undergoes large-scale conformational changes upon antigen binding, resulting in the reorientation of the CDR3 backbone and amino acid side chains ( Fig. 2e ). The mode of antigen recognition involves Nb.b201 binding its target largely through its CDR3 loop, with relatively few direct contacts between HSA and CDR1 or CDR2. Interestingly, the epitope recognized by Nb.b201 is a convex protrusion on the surface of HSA, in contrast to most nanobody epitopes, which are more typically concave. The interaction mode includes a mix of polar and nonpolar interactions, with a recurring theme of tyrosine-glutamate and tyrosineasparagine hydrogen bonds (Fig. 2c ). These results not only reveal the mechanisms of synthetic nanobody-antigen interaction, but also confirm that useful nanobodies for crystallographic applications can be obtained in a matter of two to three weeks without using specialized equipment or large-animal immunization.
Nanobodies targeting nonpurified antigen. Selection of yeast or phage surface displayed libraries is usually performed with purified and labeled protein samples. Owing to its idiosyncratic nature, protein purification remains a critical bottleneck for protein engineering by surface-display methods. This barrier proves especially steep for poorly expressed proteins, such as membrane proteins and extensively post-translationally modified protein hormones.
To assess the versatility of our yeast-based nanobody-discovery platform, we sought to develop methods enabling the use of nonpurified antigens as selection reagents. We focused our efforts on the metabolic hormone adiponectin, a complex protein with many post-translational modifications, which can only be expressed in eukaryotic cells, typically at low yields. Human adiponectin tagged with an amino-terminal FLAG epitope was expressed as a secreted protein in HEK293 cells, and the resulting medium containing a complex mixture of proteins was used as the selection antigen ( Supplementary Fig. 4a,b ). Nanobody-expressing yeast were incubated with adiponectincontaining conditioned medium, washed, and then stained with fluorescently labeled anti-FLAG M1 antibody. Adiponectin binding was confirmed for three unique clones by SPR and isolated after three rounds of MACS, followed by FACS ( Supplementary Fig. 4c ). Approaches like these may enable rapid reagent development for the large fraction of the human proteome that remains poorly characterized by biochemical methods.
Conformationally selective GPCR-binding nanobodies. While nanobodies have contributed to a broad range of biological fields, they have had a uniquely transformative impact on our understanding of GPCR biology 6 . GPCRs are the largest family of transmembrane receptors in humans, playing essential roles in every aspect of physiology ranging from function of the central nervous system to regulation of metabolism and cardiovascular biology. Nanobodies have proven to be invaluable tools for detailed structural and biochemical characterization of GPCRs, enabling profound insights into receptor structure and function. As an example, the llamaderived nanobody Nb80, which stabilizes the active conformation of the β 2 adrenergic receptor (β 2 AR), enabled determination of the first 10 1 10 7 10 2 10 3 10 4 10 5 10 6 10 1 10 7 10 2 10 3 10 4 10 5 10 6 10 1 10 7 10 2 10 3 10 4 10 5 10 6 10 1 10 7 10 2 10 3 10 4 10 5 10 6 X-ray crystal structure of the active conformation of a hormoneactivated GPCR 4 . The conformational selectivity of Nb80 was also subsequently used to probe the localization of active β 2 AR in live cells, thereby revealing a new paradigm in intracellular GPCR signaling 3 . Another nanobody, Nb35, was instrumental in examining the structure and signaling of the heterotrimeric G protein Gs in complex with β 2 AR, enabling determination of the first structure of a GPCR-G protein heterotrimer complex 21 . In recent years, the GPCR-binding nanobody repertoire has broadened to include a range GPCRs 6 . However, all GPCR-targeting nanobodies reported to date trace their origins to animal immunization, a technique that is slow, expensive, and often unsuccessful. Given the broad utility of conformationally selective antibodies in GPCR research, any in vitro platform aiming to supplant immunization-based methods must be able to generate conformationally selective GPCR binders. Hence, we sought to identify nanobodies that selectively bind the active conformation of β 2 AR using our synthetic nanobody library platform (Fig. 3) . Nanobody-displaying yeast were first selected for binding to purified, FLAG-tagged β 2 AR bound to the agonist BI167107 by MACS. We subsequently introduced a counterselection strategy to deplete undesired clones, which included nanobodies that bind the M1 antibody itself, the Alexa Fluor 647 fluorophore, conformationally invariant epitopes, or the inactive β 2 AR conformation. For example, in the third MACS round, we first depleted clones that bound to β 2 AR occupied by the high-affinity antagonist carazolol before enriching clones that bound agonist-occupied receptor. To enrich for the desired agonistbound β 2 AR-specific nanobodies, we performed two rounds of FACS. Here, the yeast library was incubated simultaneously with both BI167107-and carazolol-occupied β 2 AR, with each receptorligand complex labeled with a specific Alexa fluorophore (Fig. 3a-c) . This specialized selection using FACS requires a cell-based display system. As an indication that the selected clones bind the desired epitope, we observed that a large fraction were competitive with Nb6B9, a previously affinity-matured variant of Nb80 that binds with high affinity to the intracellular side of β 2 AR 22 . Finally, we performed a round of MACS with a decreased concentration of agonist-bound β 2 AR to enrich the highest-affinity clones (Fig. 3c) .
Sequencing individual clones revealed that we isolated 13 unique nanobodies that bound agonist-occupied β 2 AR ( Fig. 3d and Supplementary Fig. 5 ). We further prioritized clones with on-yeast titrations, which demonstrated that the isolated nanobodies have a range of affinities for the β 2 AR-BI167107 complex in the low-tomidnanomolar range. We anticipate that conformationally selective nanobodies identified from this library will find utility in biochemical, structural, and cell biological applications. Therefore, we next validated the active-state-specific β 2 AR nanobodies in pharmacological, crystallographic, and cellular signaling experiments. Four clones were selected for further characterization and were expressed and purified from E. coli. Each of the four nanobodies increased agonist affinity of β 2 AR, as assessed by a competition radioligand binding assay (Fig. 3e ). This gold-standard pharmacological assay provides definitive evidence that each nanobody stabilizes the active conformation of β 2 AR. Next, we determined binding affinities of each nanobody for BI167107-occupied β 2 AR by SPR using singlecycle kinetics (Fig. 3f,g) . Measured affinities ranged from 44 nM to 151 nM, comparing favorably to the most extensively studied llama-derived GPCR-targeting nanobody, Nb80, which binds with roughly 140 nM affinity 22 .
We next tested whether this conformational stabilization is sufficient to enable crystallization of an agonist-bound β 2 AR. Likely owing to conformational dynamics in the agonist-bound state 23 , all previous attempts to crystallize the β 2 AR-BI167107 complex have failed in the absence of an intracellular binding nanobody or the heterotrimeric G protein 4, 22, 24 . Because of the low throughput of crystallography experiments, we selected one nanobody, Nb.c200, for crystallization trials. The nanobody readily copurified with β 2 AR (Fig. 3h ) and crystallized easily by the lipidic cubic-phase method ( Fig. 3i ). Of note, Nb.c200 enabled crystallization in a range of crystallization conditions, rather than just a small subset.
Additionally, we assessed the potential of our synthetic nanobodies to modulate GPCR signaling in live cells, a key application of llama-derived nanobodies 3, 25 . As with llama-derived nanobodies, we found that our synthetic nanobodies could substantially impair β 2 AR signaling in response to adrenaline. Among the nanobodies tested, we found that Nb.c203 was the most effective, reducing adrenaline E max by 45% (Fig. 3j ). The observed variability in maximal signaling inhibition is probably reflective of both nanobody affinity and stability in the reducing environment of the cytosol. The effectiveness of Nb.c203, despite its lower-affinity binding, highlights the importance of testing multiple unique clones for intrabody applications. Notably, the insurmountable inhibition observed in the presence of these nanobodies is consistent with a G-protein-competitive binding mode for the nanobodies. Unlike an orthosteric inhibitor, adding excess agonist cannot overcome nanobody inhibition, because the site of binding is distinct.
In order to further examine the versatility of our nanobody library, we sought to identify conformationally selective nanobodies recognizing another GPCR. As a test case, we chose the human A 2A adenosine receptor (A 2A R). This receptor has long been known to play important roles in the central nervous system and has recently emerged as a target for cancer immunotherapy drug development 26 . Importantly, there are no active-state-selective nanobodies targeting A 2A R, although an inactive-state-specific Fab has been reported 27 . To generate active-state-specific nanobody clones, we performed two rounds of MACS to generate a library of A 2A Rbinding nanobodies followed by one round of FACS to enrich conformationally selective binders (Fig. 4a ). From this pool, two clones called Nb.AD101 and Nb.AD102 were chosen for further characterization. In a flow cytometry-based binding assay, each of these clones showed a strong preference for agonist-bound A 2A R (Fig. 4b) .
To further validate these clones, we expressed and purified them and measured binding to receptor in an in vitro pulldown assay. Consistent with cell-based staining experiments, these nanobodies showed binding exclusively to agonist-occupied receptor (Fig. 4c ), confirming the generalizability of the approach.
Taken together, these data show that conformationally selective nanobodies identified by our in vitro platform recapitulate all key features of llama-derived clones. In addition, the large diversity of conformationally selective clones identified from the synthetic library may enable a larger repertoire of applications; some may perform better as crystallographic chaperones, others may be more stable in the reducing intracellular environment or have increased specificity required for identifying a specific protein in a complex milieu.
Discussion
Antibodies and their minimal binding fragments have transformed biomedical research. Nanobodies, derived from camelid heavy chain antibodies, have emerged as particularly powerful research tools in large part because of their ability to detect and stabilize specific conformations for GPCRs and other biochemically challenging proteins. However, despite their broad utility, nanobodies have only been exploited for a subset of potential applications, owing to challenges associated with nanobody discovery. Foremost among these challenges is the requirement for camel, llama, or alpaca immunization, a slow and expensive process requiring large quantities of purified protein and access to large-animal husbandry and veterinary facilities. Moreover, this process frequently yields only small numbers of nanobody clones, many or all of which may not possess the desired activity. Our approach reported here addresses these challenges by providing a fully in vitro platform for nanobody discovery based on an engineered library displayed on S. cerevisiae.
To assess the utility of our library, we selected nanobodies targeting a diverse array of antigens: soluble proteins, nonpurified proteins, and two human GPCRs. In each case, our platform enabled identification of nanobody clones capable of binding to the target antigen with the desired activity. To date, all nanobody-selection efforts conducted with this library have led to the successful isolation of clones with submicromolar affinity, with the exception of an effort targeting FLAG peptide, a short unstructured sequence. Strikingly, with the addition of FACS enrichment to our selection methodology, the affinities of our synthetic β 2 AR-binding clones were comparable to or better than that of the most extensively studied GPCR-targeting nanobody, the llama-derived Nb80.
While there are many potential selection strategies that enable nanobody identification, we demonstrate that a combination of MACS and FACS enrichments provides a rapid approach to the identification of nanobodies selective for a particular target or to a specific conformation. Early MACS rounds enable depletion of large pools of non-binding clones, rapidly reducing library diversity by two to three orders of magnitude. However, MACS-based counterselection strategies suffer from poor precision, and identification of clones specific for a target or conformational states often requires many iterations for sufficient enrichments. Given the throughput of modern FACS instruments, we opt to leverage the precision afforded by fluorescence-based selections as early in the selection scheme as possible, usually after two rounds of MACS to reduce library diversity to a manageable level. Though it is possible that this approach may miss the single highest-affinity clone in the library, nanobodies are readily amenable to affinity maturation to improve affinity, even for difficult targets such as GPCRs 22 . Importantly, our library generates nanobody binders that are amenable to crystallization and subsequent structural determination, and thus, it demonstrates considerable promise as a tool to aid structural studies.
From soluble protein binders to conformationally selective GPCR stabilizers, our platform allows straightforward, rapid, and low-cost isolation of nanobodies, even with highly specialized functionalities. To facilitate broad deployment of this resource, we have made the library publicly available and free of charge for nonprofit use. Detailed protocols for nanobody-binder selection are included in the Supplementary Note and can be adapted or modified to enable more diverse applications. We envision that rapid and simple nanobody discovery will be an enabling resource for applications throughout biomedical research.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0028-6.
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Methods Cell lines. Expi293 cells (Thermo Fisher Scientific) were used to create a stable cell line secreting FLAG-adiponectin. Cells were maintained using a bioreactor (CELLine Flasks, Wheaton). The cell growth medium of the lower and upper chamber comprised Expi293 Expression Medium (Thermo Fisher) supplemented with 10% FBS (Zen-Bio) and 10 μ g/mL gentamicin (VWR) and FreeStyle 293 Expression Medium (Life Technologies) supplemented with 10 μ g/mL gentamicin (VWR), respectively. Human β 2 AR and A 2A R were purified from infected Sf9 cells grown in ESF 921 media (Expression Systems). HEK293T cells (ATCC) for β 2 AR signaling assays were grown at 37 °C and 5% CO 2 in DMEM (+ 4.5 g/l-glucose, + l-glutamine, no sodium pyruvate; VWR) supplemented with 10% FBS (USA Scientific).
Nanobody library construction. The DNA library of nanobodies was constructed by two-step overlap-extension PCR (OE-PCR). A set of ten primers, P1_for, P2_ rev… P10_rev (Keck Biotechnology Resource Laboratory; Supplementary Table 2) , were dissolved at 100-µ M concentration and mixed in an equimolar ratio to prepare three mixed pools containing each primer at a concentration of 10 µ M. The three mixed pools, 'mix short' , 'mix medium' , and 'mix long' , differed in the P9 primers, using P9a_for, P9b_for, or P9c_for to introduce a CDR3 region of variable length of 7, 11, or 15 randomized residues respectively. 1 µ L of each mixed pool at 10-µ M concentration and at five-fold sequential dilutions was subsequently used to prepare 50 µ l OE-PCR reactions using Phusion polymerase. 0.4 µ M of each primer, or a 25-fold diluted stock, was found to produce optimal yields for OE-PCR for each of the three mixed pools. The full-length nanobody DNA product from each pool was mixed in a 1:2:1 molar ratio of short/medium/long CDR3 regions, referred to as the nanobody DNA library pool hereafter, recapitulating the length distribution frequencies observed in camelid V HH domains. Validation of the biochemical tractability of these synthetic nanobodies was carried out in E. coli by amplifying the resulting mixture with primers pET26b_NbLib_GA_for and pET26b_NbLib_GA_rev and cloning into pET26b.
The nanobody DNA library pool was successively amplified for yeast transformations with pYDSFor1-pYDSRev1, pyDSFor2-pYDSRev2, and pYDSFor3-pYDSRev2 primers. 500 mL of BJ5465 yeast (MATα ura352 trp1 leu2Δ1 his3Δ200 pep4::HIS3 prb1Δ1.6 R can1 GAL) were grown to OD 600 1.5 and transformed with 245 µ g nanobody insert DNA and 50 µ g of pYDS649 plasmid, and digested with NheI-HF and BamHI-HF (New England BioLabs), using an ECM 830 Electroporator (BTX-Harvard Apparatus). Dilutions of transformed yeast were then plated on dropout medium without tryptophan (-Trp) as single colonies to obtain an estimate of library diversity.
Three cultures of 5 × 10 5 yeast were inoculated in dropout medium with tryptophan (US Biological) and grown overnight at 30 °C for whole-library nextgeneration sequencing reactions. From these cultures, PCRs were performed on 8 × 10 6 pelleted yeast to amplify nanobody genes using three sets of primers with different barcodes: Batch1For-Batch1Rev, Batch2For-Batch2Rev, and Batch3For-Batch3Rev. A sequencing library was prepared using PrepX (Wafergen), and sequencing was performed by a MiSeq (Illumina) with 10% PhiX. Next-generation sequencing of HSA-binding nanobody selection rounds was performed similarly starting with 2 × 10 5 yeast cells in the initial inoculum and using the primers Rd1For-Rd1Rev, Rd2For-Rd2Rev, Rd3For-Rd3Rev, and Rd4For-Rd4Rev.
Optimization of yeast display plasmid is summarized in Supplementary Fig. 2 . SIRPα mutant CV1 and CD47 proteins used for the assay were expressed and purified as described previously 28 . Analytical yeast staining experiments were performed as described below, using yeast strain BJ5465 as in other experiments.
Isolation of nanobody binders from library. HSA. Initially, 2.5 × 10 9 induced yeast for the first round and 1.4-5 × 10 7 induced yeast for subsequent rounds were washed and resuspended in buffer (20 mM HEPES, pH 7.5, 150 mM sodium chloride, 0.1% (w/v) ovalbumin, 1 mM EDTA) and then incubated with anti-Alexa Fluor 647 or anti-FITC microbeads (Miltenyi) at 4 °C for 30 min. Each round of MACS selection began with a preclear step which involved passing the yeast through an LD column (Miltenyi) to remove yeast-expressing nanobodies that bound nonspecifically to magnetic beads. After preclearing, HSA-binding nanobodies were enriched over four rounds of MACS selection by staining the yeast alternately with Alexa Fluor 647-or FITC-labeled HSA (Sigma) and microbeads, then passing them through an LS column (Miltenyi). During these four selection rounds, yeast were stained with successively lower concentrations of HSA: 1 μ M, 250 nM, 75 nM, and 15 nM, in order to enrich for binders with higher affinities. After MACS selection, yeast was plated as single colonies, which were picked and grown as clonal populations in a 96-well plate. Following galactose induction of nanobodies, yeast were stained with Alexa Fluor 488-labeled HSA and analyzed by flow cytometry with an Accuri C6 (BD Biosciences) to screen for nanobody binders.
Human adiponectin. The adiponectin-containing supernatant taken from the bioreactor cell culture was used as the selection reagent, with no purification performed. An approximate concentration of secreted FLAG-adiponectin in the supernatant was estimated by dividing the average yield of pure adiponectin obtained for each harvest by volume of supernatant.
For the first round of selection, 5 × 10 9 induced yeast were washed and incubated in buffer (20 mM HEPES, pH 7.5, 150 mM sodium chloride, 2 mM CaCl 2 , 0.1% BSA, 1.8% maltose) with Alexa647-labeled anti-FLAG M1 and anti-647 microbeads. Clones binding nonspecifically to the staining reagents were removed by passage through an LD column, and the remaining yeast from the flow-through were incubated with unpurified FLAG-adiponectin at ~500 nM for 30 min at 4 °C. Cells were then stained with anti-FLAG-647 and anti-647 microbeads. Binding clones were enriched via magnetic selection in an LS column and cultured overnight in -Trp medium at 30 °C. Rounds 2 and 3 of selection were performed similarly with 3 × 10 7 induced yeast and cells washed, stained with 647-or FITC-labeled M1, and labeled with anti-Alexa Fluor 647 or anti-FITC microbeads before magnetic separation during rounds 2 and 3, respectively.
Following round 3, induced cells incubated with ~500 nM unpurified adiponectin and stained simultaneously with M1-647 and M1-FITC to differentiate dye-, antibody-, and adiponectin-binding clones. FACS was used to enrich for cells that exhibited adiponectin-dependent 647 and FITC staining. Nanobodies from individual clones were sequenced and purified, and adiponectin binding was confirmed and characterized by SPR with purified adiponectin.
Human β 2 AR. To isolate agonist-specific β 2 AR-binding nanobodies, two rounds of MACS were performed with 1 μ M purified, FLAG-tagged β 2 AR bound to the high-affinity agonist BI167107 and FITC-or Alexa Fluor 647-labeled anti-FLAG antibody in a selection buffer containing 20 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% dodecylmaltoside (DDM, Anatrace), 0.01% CHS, 0.05% BSA, 5 mM CaCl 2 , and 10 mM maltose. For round 2 of selection, the yeast library was precleared, as detailed above, with anti-FLAG antibody labeled with Alexa Fluor 647 to deplete antibody or fluorophore binders. Round 3 used MACS again, but counterselection was performed against β 2 AR bound to the high-affinity antagonist carazolol to deplete nanobody clones that bind conformationally invariant or inactivestate epitopes. In subsequent rounds, we used FACS to more specifically select nanobodies that selectively bind β 2 AR in the active conformation. In round 4, yeast were simultaneously incubated with 1 μ M β 2 AR-BI167107 complex labeled with Alexa Fluor 647 NHS ester and 1 μ M β 2 AR-carazolol complex labeled with Alexa Fluor 488 NHS ester. Yeast displaying selectivity for agonist (high Alexa Fluor 647 signal and low Alexa Fluor 488 signal) were collected, expanded in growth media, induced, and subjected to another round of FACS. The conformational selection procedure was repeated as in round 4; however, the fluorophores coupled to agonist and antagonist was switched to deplete nonspecific clones. A final MACS round was performed at 30 nM β 2 AR-BI167107 to isolate the highest affinity nanobodies. Nanobodies from individual clones were subsequently sequenced and purified for biochemical and biophysical studies.
Human adenosine A 2A receptor. Two rounds of MACS were performed with 1.5 μ M of FLAG-tagged A 2A R bound to the agonist 5′ -N-ethylcarboxamidoadenosine (NECA) and M1 anti-FLAG antibody labeled with FITC or Alexa Fluor 647 in a selection buffer containing 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% MNG, 0.01% CHS, 2 mM CaCl 2 , and 0.2% maltose. Each round began with a preclearing step as detailed above. To isolate conformationally selective binders, the secondround yeast were stained for 20 min simultaneously with 500 nM each of A 2A R bound to the agonist UK 432097 and A 2A R bound to the antagonist ZM 241385, which were labeled with secondary anti-FLAG M1 488 and anti-FLAG M1 647, respectively. Yeast that selectively bound receptor in complex with the agonist UK 432097 were isolated with FACS. Individual clones were grown and stained with both receptor populations to confirm binding selectivity and on-yeast binding titrations were performed to approximate binding affinities. Nanobodies were then purified, and binding was confirmed in vitro with an anti-FLAG pulldown.
Protein expression and purification. The ADIPOQ gene was cloned into a pTARGET vector so that an HA signal peptide directs secretion of N-terminally FLAG-tagged adiponectin into the medium. Cells from the lower chamber of the bioreactor were harvested by centrifugation at 4,000 g for 10 min. The supernatant was diluted 1:1 with buffer (20 mM HEPES, pH 7.5, 150 mM sodium chloride, 2 mM CaCl 2 2 mM) before loading onto FLAG resin. FLAG resin was first washed with 20 mM HEPES, pH 7.5, 300 mM NaCl, 2 mM CaCl 2 and then with 20 mM HEPES, pH 7.5, 150 mM NaCl, and 2 mM CaCl 2 . Adiponectin was eluted with buffer comprised of 150 mM NaCl, 20 mM HEPES, pH 7.5, 0.2 mg/mL FLAG peptide, and 5 mM EDTA and then dialyzed overnight into 20 mM HEPES, pH 7.5, and 150 mM sodium chloride.
Human β 2 AR fused to an amino-terminal hemagglutinin signal peptide and FLAG-tag as well as a carboxy-terminal 1D4 tag was purified from infected Sf9 cells. Cells were collected 64 h after baculoviral infection and stored at -80 °C. For receptor preparations used during nanobody selections, purification was performed using ligand-affinity chromatography as described previously 29 . For biophysical assays, we used a simpler purification method omitting ligand-affinity chromatography. Cells were lysed in a buffer comprised of 20 mM HEPES, pH 7.5, 2 mM MgCl 2 , 2 µ l benzonase, and 1 µ M ICI-118,551. The resulting lysate was centrifuged, and the pellets were resuspended in solubilization buffer containing 20 mM HEPES, pH 7.5, 200 mM NaCl, 10% glycerol, 1% MNG, 0.1% CHS, and 1 µ M ICI-118,551, then incubated at 4 °C for 2 h. The insoluble fraction was separated by centrifugation at 39,000 g for 20 min, and the supernatant was loaded over 5 mL of homemade anti-FLAG M1 resin. FLAG resin was subsequently washed with 20 mM HEPES, pH 7.5, 200 mM NaCl, 10% glycerol, 0.1% MNG, and 0.01% CHS. β 2 AR was eluted in the same buffer with a lower concentration of detergent and CHS (0.01% and 0.001%, respectively) supplemented with 5 mM EDTA and 0.2 mg/mL FLAG peptide. Receptor was further purified by size-exclusion chromatography in the presence of agonist BI167107. For crystallographic experiments, β 2 AR fused to an amino-terminal T4 lysozyme 30 was similarly purified.
Isolated nanobody genes were cloned into the periplasmic expression vector pET26b containing a C-terminal 6 × histidine tag and expressed from BL21 (DE3) E. coli. For each purification, E. coli were grown in Terrific Broth (Research Products International) and induced after reaching OD 600 0.6-0.8 with 1 mM IPTG (Gold Biotechnology) at 25 °C for about 15 h. Induced cells were pelleted and resuspended in 100 mL of buffer consisting of 0.5 M sucrose, 0.2 M Tris, pH 8, 0.5 mM EDTA and osmotically shocked by adding 200 mL of water with 45 min of stirring, releasing periplasmic nanobody. The lysate was brought to a concentration of 150 mM NaCl, 2 mM MgCl 2 , and 20 mM imidazole and then centrifuged at 20,000 g for 20 min at 4 °C. The supernatant was applied to a gravity column with 3 mL of Ni Sepharose 6 Fast Flow (GE Healthcare). The resin was washed with a high-salt buffer (20 mM HEPES, pH 7.5, 500 mM NaCl, 20 mM Imidazole) and then washed with NH7.5 buffer (20 mM HEPES, pH 7.5, 100 mM NaCl) + 20 mM imidazole, and nanobodies were eluted with NH7.5 + 400 mM imidazole. Nanobodies used for crystallography were treated to carboxypeptidase A (Sigma) and B (Roche) to remove the histidine tag, dialyzed into HBS buffer (10 mM HEPES, pH 7.4, 150 mM NaCl), and copurified with their respective binding partners over an S200 size-exclusion column (GE Healthcare).
Human A 2A R was fused at the N terminus to an HA signal sequence followed by a FLAG epitope, and at the C terminus, it was truncated at Ala317 with the insertion of a 9 × histidine tag. The receptor was expressed in Sf9 insect cells following generation of BestBac Baculovirus (Expression Systems) mediated by the pVL1393 vector. Membranes from three 1-l cultures were prepared essentially as described previously 31 and solubilized in 1% DDM, 0.1% CHS, 20 mM HEPES, pH 7.5, 800 mM NaCl, 10% glycerol, 4 mM theophylline, 5 μ g/ml leupeptin, 5 μ g/ml benzamidine, 2 mg/ml iodoacetamide, and 100 μ M TCEP. Following centrifugation, the supernatant was incubated overnight with Ni 2+ chelating Sepharose under rotation at 4 °C. The resin was transferred to a column and washed in five column volumes of ice-cold wash buffer (0.1% DDM, 0.01% CHS, 20 mM HEPES, pH 7.5, 800 mM NaCl, 10% glycerol, 4 mM theophylline, 5 μ g/ml leupeptin, 5 μ g/ml benzamidine) containing 25 mM imidazole and repeated with 50 mM imidazole. The A 2A R was eluted in the same buffer with 200 mM imidazole added. A 2A R was loaded onto an anti-FLAG M1 antibody column (Sigma) at room temperature in the presence of 2 mM CaCl 2 . Theophylline was washed out in exchange for UK-432097 (30 μ M) or ZM-241385 (30 μ M) in buffer containing 0.1% DDM, 0.01% CHS, 20 mM HEPES, pH 7.5, 100 mM NaCl, 10% glycerol, and 2 mM CaCl2. The elution was performed at room temperature in the same buffer with the exclusion of CaCl 2 and in the presence of 5 mM EDTA and 0.2 mg/mL FLAG peptide. The purified receptor was dialyzed overnight at 4 °C into the same buffer used for anti-FLAG column washes excluding CaCl 2 . Following the addition of 15% glycerol, 1-nmol aliquots of A 2A R were flash frozen in liquid nitrogen.
Characterization of nanobody binding. Binding of Nb.b201 with HSA or MSA (Sigma) was qualitatively assessed by mixing the proteins in a 1.2:1 ratio, respectively, and separating through a Superdex 200 10/300 gel filtration column (GE Healthcare) in HBS buffer.
For SPR of Nb.b201, EZ-Link NHS-PEG4-Biotin (Thermo Fisher Scientific) labeled recombinant HSA from S. cerevisiae (HSAr; Sigma) or MSA were immobilized to a Series S Sensor Chip SA using a Biacore T200 (GE Healthcare). Dilutions of Nb.b201 in running buffer (10 mM HEPES, pH 7.5, 150 mM NaCl, 0.03% Tween) were made and the sample was injected at a flow rate of 30 µ l/minute with a contact time of 120 s and dissociation time of 300 s. For SPR of β 2 AR-binding nanobodies, β 2 AR was labeled with NHS-PEG4-Biotin and immobilized on a Sensor Chip CAP (GE Healthcare). Dilutions of β 2 AR were made in running buffer (10 mM HEPES, pH 7.5, 150 mM NaCl, 0.01% MNG, 0.001% CHS, 20 nM BI167107), and the sample was injected at a flow rate of 30 μ l/min with a contact time of 240 s and dissociation time of 700 s.
For SPR of Nb.AQ103, EZ-Link NHS-PEG4-Biotin-labeled (Thermo Fisher Scientific) FLAG-adiponectin was immobilized to a Series S Sensor Chip SA using a Biacore T200 (GE Healthcare). Dilutions of Nb.AQ103 in running buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.05% Tween) were made, and the sample was injected at a flow rate of 30 µ l/minute with a contact time of 150 s and dissociation time of 500 s.
For SEC-MALS, a 1.4:1 molar mix of Nb.b201 and HSAr, as well as Nb.b201and HSAr-alone controls, were injected into an AdvanceBio 300 Å column (Agilent) using an Agilent 1260 Infinity Isocratic Liquid Chromatography System and characterized using a Wyatt DAWN HELEOS II Multi-Angle static Light Scattering detector.
For the HIS-pulldown assay, 5 μ M Nb.AQ103 was incubated with Ni 2+ resin at 4 °C for 1 h, and then the excess was removed by washing with HBS and then incubated with the adiponectin globular domain at 4 °C for 1 h. The reaction was washed with HBS and 20 mM imidazole and eluted with HBS in presence of 250 mM imidazole.
Validation of conformationally selective β 2 AR nanobodies. For radioligand binding studies, β 2 AR was reconstituted into high-density lipoprotein (HDL) nanodiscs containing a 3:2 molar ratio of POPC/POPG as described previously 32 . Binding experiments were performed with 150 fmol β 2 AR. Saturation binding was first performed using 3 H-dihydroalprenolol ([ 3 H]DHA; PerkinElmer), yielding a K D of 0.7 nM. Competition binding experiments to measure adrenaline affinity in the presence and absence of nanobodies were carried out in a binding buffer comprised of 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% BSA, and 1 mM EDTA containing 2 nM [ 3 H]DHA, 150 fmol β 2 AR, and a range of adrenaline concentrations 10 −4 -10 −11 M. Nanobodies were used at a final concentration of 5 µ M. Reactions were incubated for 1.5 h at room temperature before rapid filtration with a Brandel 96-well harverster onto a filter pretreated with 0.1% polyethyleneimine. Bound [ 3 H]DHA was measured by liquid scintillation counting. Measurements were performed in triplicate and are expressed as mean ± s.e.m. β 2 AR cAMP signaling assay. β 2 AR signaling was measured using a transcriptional CRE-SEAP (secreted embryonic alkaline phosphatase) reporter to indirectly measure cAMP production 33 . Briefly, HEK293T cells were seeded at 3.3 × 10 4 cells/ well in 96-well plates the day before transfection in 200 μ L/well of DMEM. The following day, medium was aspirated from the cells and replaced with 50 μ L of serum-free DMEM, and cells at 70% confluency were transfected in triplicate with Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. Each well was transfected with 10 ng of pcDNA3.1(+ ) encoding β 2 AR, 20 ng of CRE-SEAP reporter plasmid (BD Biosciences), and 20 ng of pEGFP-N1. Plasmids included conformationally selective β 2 AR nanobodies (Nb.c200-c203), and the pEGFP-N1 empty vector. After six hours of incubation at 37 °C, the transfection mix was aspirated from the cells, and 200 μ L of serum-free DMEM was added with the indicated final concentrations of adrenaline. The cells were incubated at 37 °C for 48 h, then at 70 °C for 2 h. To determine SEAP activity, the substrate 4-methylumbelliferyl phosphate (Sigma Aldrich) was prepared at 1.2 mM in 2 M diethanolamine bicarbonate pH 10 and mixed with an equal volume of cell supernatant at room temperature for 10 min. Fluorescence was measured on an EnVision 2103 Multilabel Reader (Perkin Elmer) with an excitation wavelength of 360 nm and an emission wavelength of 449 nm. For each condition, the baseline fluorescence value was determined from cells not treated with adrenaline and was subtracted from every value in the dataset. β 2 AR signaling was calculated as a fraction of the maximum observed response (pEGFP-N1 empty vector) and plotted using GraphPad Prism. refinement. Crystallographic data analysis was performed with xds and phenix. refine, using standard metrics to assess structure quality. In the final Ramachandran plots, the favored and allowed residues were 97.5% and 2.5%, respectively, for Nb.b201 in isolation and 97.4% and 2.6%, respectively, for the HSA-Nb.b201 complex. Full details of crystallographic statistics are summarized in Table 1 .
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. Atomic coordinates and structure factors for the nanobody structures are deposited in the Protein Data Bank under the accession codes PDB 5VNV (Nb.b201 alone) and PDB 5VNW (Nb.b201 in complex with human serum albumin). All other data are available upon reasonable request.
